10-Q: DSS Reports Q2 2025 Losses Amid Revenue Growth & Asset Sales

DSS, Inc. reported a 27% increase in total revenue for the first half of 2025, reducing its net loss by 21%, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Total revenue for the six months ended June 30, 2025, increased by 27% to $10,237,000, up from $8,082,000 in the prior year period.
• Net loss for the six months ended June 30, 2025, decreased by 21% to $(7,902,000), compared to $(10,063,000) in the same period of 2024.
• Net loss attributable to DSS common stockholders was $(6,929,000) or $(0.78) per share for the six months ended June 30, 2025, an improvement from $(8,754,000) or $(1.24) per share in 2024.
• Cash and cash equivalents decreased to $9,384,000 as of June 30, 2025, from $11,431,000 at December 31, 2024.
• The company generated $430,000 in cash from operating activities for the six months ended June 30, 2025, a significant improvement from using $5,574,000 in the prior year.
• Investing activities provided $10,135,000 in cash, primarily from the sale of the Plano, TX facility for $9,500,000 and related party investments for $1,500,000.
• Financing activities used $12,512,000 in cash, mainly due to payments of long-term debt ($9,443,000) and margin loans ($3,178,000).
• Product Packaging revenue increased by 25% to $8,286,000, and Securities revenue increased by 45% to $1,900,000 for the six months ended June 30, 2025.
• Commercial Lending revenue decreased by 79% to $29,000, largely due to loans going on non-accrual.
• Biotechnology retail sales increased by 950% to $21,000 for the six months ended June 30, 2025.
• The company recorded a $600,000 impairment of intangible assets related to resigning as the registered investment advisor of American First Mutual Funds.
• Several notes receivable, including those from Puradigm, Asili, WUURII, BMIC, and VEII, are in default or fully reserved for.

Sentiment

Score: 2

Explanation: The company faces substantial doubt about its ability to continue as a going concern, has persistent operating losses, significant loan defaults, and material weaknesses in internal controls. While revenue increased and net loss decreased, these improvements are overshadowed by fundamental financial instability and delays in asset sales. The extensive related-party transactions also add a layer of concern.

Positives

• Total revenue increased by 27% for the six months ended June 30, 2025, reaching $10,237,000.
• Net loss decreased by 21% to $(7,902,000) for the six months ended June 30, 2025, indicating improved financial performance compared to the prior year.
• Net cash provided by operating activities was $430,000 for the six months ended June 30, 2025, a substantial improvement from cash used of $5,574,000 in the prior year.
• Product Packaging revenue grew by 25% to $8,286,000, driven by new and existing customer orders.
• Securities revenue increased by 45% to $1,900,000, primarily due to new tenants at the AMRE LifeCare Pittsburgh facility beginning rental payments.
• Biotechnology retail sales saw a significant increase of 950% to $21,000.
• The company successfully sold its Plano, TX facility for $9,500,000, contributing to cash from investing activities.

Negatives

• The company reported a net loss of $(7,902,000) for the six months ended June 30, 2025, and has incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, raising substantial doubt about its ability to continue as a going concern.
• Cash and cash equivalents decreased by $2,047,000 from December 31, 2024, to June 30, 2025.
• Commercial Lending revenue decreased significantly by 79% to $29,000, primarily due to a number of loans going on non-accrual as borrowers struggled to make payments.
• An impairment of intangible assets totaling $600,000 was recorded due to the company resigning its position as the registered investment advisor of American First Mutual Funds.
• A loss of $727,000 was incurred on the sale of the Plano, TX facility.
• Several notes receivable, including those from Puradigm ($5,544,000), Asili, LLC ($884,000), WUURII Commerce, Inc. ($465,000), BMI Capital, Inc. ($83,000 and $110,000), and VEII, Inc. ($917,000), are in default or fully reserved for, indicating significant credit weaknesses.
• Material weaknesses in disclosure controls and procedures were identified and remain as of June 30, 2025.
• The reclassification of $35.4 million in real estate assets from 'held for sale' to 'investments in real estate, net' indicates that the sale of these properties is no longer expected to be finalized within 12 months.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to ongoing operating losses and negative cash flows from operating and investing activities over the past two years.
• The company's ability to generate operating cash and meet working capital needs relies on the sale of marketable securities ($9.8 million) and real estate holdings ($35.4 million), as well as obtaining equity and/or debt-based financing.
• Significant credit risk exists in the loan portfolio, with several notes receivable in default or fully reserved for, indicating potential for further loan losses.
• Material weaknesses in disclosure controls and procedures persist, which could adversely affect the company's ability to record, process, summarize, and report financial information accurately and timely.
• The company is exposed to concentration of credit risk, with one customer accounting for approximately 25% of consolidated revenue and three customers accounting for 18%, 15%, and 11% of trade accounts receivable as of June 30, 2025.
• The company's investments in equity securities without readily determinable fair value are recorded at cost, less impairment, plus or minus adjustments related to observable transactions, which introduces valuation uncertainty.
• The company's business lines operate in diverse and competitive markets, including product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing, each with inherent market and operational risks.

Future Outlook

The company believes it will have access to sources of capital from the sale of its equity securities and debt financing, and thus has sufficient cash to meet its requirements for at least the next 12 months. It also plans to continue measures to materially reduce expenses and cash burn across all corporate and business lines. The merger of Impact BioMedical Inc. with Dr Ashleys Limited is expected to close during the fourth quarter of 2025.

Management Comments

• The increase in Printed Product revenue is driven by new customer orders as well as existing customer orders exceeding their forecasts.
• The increases in Securities revenue are driven by an increase in rental income by new tenants at AMRE LifeCare Pittsburgh facility beginning to making rental payments in the second half of 2024.
• The decreases in Commercial lending revenue are due to a number of loans made going on non-accrual as borrowers have struggled to make expected payments.
• Sales, general and administrative compensation costs increased primarily due to a bonus awarded to Heng Fai Holdings Limited, beneficially owned by Mr. Heng Fai Ambrose Chan, Director of DSS, Inc., for services rendered.
• Professional fees decreased due to efforts taken to decrease these costs as the company continues to drive savings in non-essential areas.
• Research and development costs decreased primarily due to decreased efforts in this area post Impact Bio's IPO in September 2024.
• Other operating expenses decreased primarily due to collections of previously written-off accounts receivable associated with AMRE LifeCare facilities of approximately $600,000.
• The decrease in interest income is driven by several notes being put on non-accrual as the related borrowers have shown an inability to pay timely.
• The decrease in loss on investment is driven by the performance of our stock portfolio, driven by the sale of Impact Bio stock acquired at the time of its IPO.

Industry Context

DSS operates a highly diversified portfolio across product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing. The growth in product packaging and securities (REIT) segments suggests resilience in specific niches, while the significant decline in commercial lending revenue due to loan defaults highlights challenges in its financial services arm, potentially reflecting broader economic pressures or specific credit risk management issues. The biotechnology segment, while small in revenue, shows high growth, indicating potential in its niche products like air purification. The company's strategy of acquiring equity positions in undervalued entities and developing new technologies positions it across various growth sectors, but also exposes it to diverse market risks.

Comparison to Industry Standards

• The filing does not provide specific industry benchmarks or comparable company data to assess performance against industry standards. Therefore, a direct comparison is not feasible based solely on the provided information.
• The significant number of loan defaults and fully reserved notes in the Commercial Lending segment suggests a higher-than-average risk profile or less stringent underwriting standards compared to traditional commercial banks.
• The substantial doubt about the company's ability to continue as a going concern is a critical indicator that its financial health is below typical industry standards for publicly traded companies.

Management Changes

Corporate Governance

Legal Proceedings

• The LifeCare Agreement with Pinnacle Bank is in default, and demand was made for final payment by December 22, 2023. This amount is past due as of June 30, 2025.
• The Pinnacle Loan with Pinnacle Bank (assumed by SMS Financial) is in default, and demand was made for final payment by December 22, 2023. This amount is past due as of June 30, 2025.

Related Party Transactions

• The company owns approximately 4% of Alset International Limited (Alset Intl), where Chairman Heng Fai Ambrose Chan is Executive Director, CEO, and majority shareholder. The fair value of this investment was $2,098,000 as of June 30, 2025, with an unrealized loss of $420,000 for the six months ended June 30, 2025.
• DSS Securities, Inc. owns 24.9% of BMI Capital International LLC (BMIC), a broker-dealer. The company's chairman and another independent board member also have ownership interest in BMIC. DSS's portion of net loss in BMIC was $5,000 for the three months ended June 30, 2025.
• The company entered into a Stock Purchase Agreement with Alset EHome International Inc. (AEI), where Executive Chairman Heng Fai Ambrose Chan is Chairman, CEO, and largest shareholder. AEI agreed to sell a subsidiary holding shares of True Partner Capital Holding Limited in exchange for DSS common stock.
• DSS Financial Management Inc. and BMIC (related party) entered into a promissory note (Note 8) for $100,000, due August 29, 2025. The outstanding principal and interest of $83,000 was fully reserved as of June 30, 2025.
• DSS Financial Management Inc. and BMIC (related party) entered into a promissory note (Note 9) for $102,000, due May 7, 2026. The outstanding principal and interest of $110,000 was fully reserved as of June 30, 2025.
• APF and VEII, Inc. entered into a promissory note (Note 10) for $1,000,000, due July 26, 2025. Chairman Heng Fai Ambrose Chan is on VEII's board of directors. The outstanding principal and interest of $917,000 was fully reserved as of June 30, 2025.
• LVAM entered into a loan agreement with BMIC (BMIC Loan), a related party, for $3,000,000, with a current maturity date of July 2025. Outstanding principal and interest was $464,000 as of June 30, 2025.
• LVAM entered into a loan agreement with Lee Wilson Tsz Kin (Wilson Loan), a related party, for $3,000,000, with a current maturity date of July 2025. Outstanding principal and interest was $145,000 as of June 30, 2025.
• Heng Fai Holdings Limited (HFHL), beneficially owned by Mr. Heng Fai Ambrose Chan, Director of DSS, Inc., was awarded 1,000,000 shares of the company's common stock, approximating $870,000, as bonus compensation for services rendered.
• The company completed the acquisition of certain assets owned by DSS Pure Air, Inc., a related party, for $1,150,000 to be paid by 545,024 shares of the company's common stock.

Stakeholder Impact

• Shareholders face significant risk due to the 'going concern' warning, persistent losses, and the potential for further dilution from future capital raises.
• Creditors are exposed to risk given the numerous loan defaults and the company's overall financial instability.
• Employees may face uncertainty regarding job security and compensation given the company's efforts to reduce expenses and cash burn.
• Customers in the Product Packaging and Securities segments may benefit from continued operations and growth in those areas, but customers of other segments, particularly Commercial Lending, might experience disruptions due to financial distress.
• Suppliers may face increased credit risk when dealing with the company, potentially leading to stricter payment terms or reduced business.

Next Steps

• Continue efforts to materially reduce expenses and cash burn at all corporate and business line levels.
• Monitor tax positions and Net Operating Loss (NOL) utilization, making adjustments to deferred tax asset valuation allowance as needed.
• Implement and test remediation steps for identified material weaknesses in disclosure controls and procedures.
• Impact BioMedical Inc.'s merger and share exchange agreement with Dr Ashleys Limited is expected to close during the fourth quarter of 2025.

Key Dates

Recommendation

The filing explicitly states 'substantial doubt about the Company’s ability to continue as a going concern,' which is a critical red flag for investors. Despite some revenue growth and a reduction in net loss, the company continues to incur significant operating losses and negative cash flows from investing activities. The reclassification of $35.4 million in assets from 'held for sale' to 'investments in real estate, net' indicates a failure to execute planned divestitures, further exacerbating liquidity concerns. Numerous notes receivable are in default or fully reserved, highlighting poor credit management or high-risk lending practices. The presence of material weaknesses in internal controls adds to the operational risk. The extensive related-party transactions, while disclosed, can raise questions about corporate governance and potential conflicts of interest. Given these severe financial and operational challenges, the stock carries extremely high risk, and a seasoned investor would likely recommend a strong sell.

Keywords

Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, Direct Marketing, SEC Filing, 10-Q, Financial Results, Net Loss, Revenue Growth, Going Concern, Loan Defaults, Asset Sales, Intangible Assets, Related Party Transactions, Internal Controls, Medical Real Estate, Air Purification, Investment Banking, REIT